Amgen (AMGN) Revenue (2016 - 2026)

Amgen has reported Revenue over the past 18 years, most recently at $8.6 billion for Q1 2026.

For Q1 2026, Revenue rose 5.76% year-over-year to $8.6 billion; the TTM value through Mar 2026 reached $37.2 billion, up 9.07%, while the annual FY2025 figure was $36.8 billion, 9.95% up from the prior year.
Revenue for Q1 2026 was $8.6 billion at Amgen, down from $9.9 billion in the prior quarter.
Over five years, Revenue peaked at $9.9 billion in Q4 2025 and troughed at $459.0 million in Q4 2022.
A 5-year average of $7.5 billion and a median of $8.1 billion in 2025 define the central range for Revenue.
Biggest five-year swings in Revenue: tumbled 93.3% in 2022 and later surged 1685.62% in 2023.
Year by year, Revenue stood at $459.0 million in 2022, then surged by 1685.62% to $8.2 billion in 2023, then increased by 10.86% to $9.1 billion in 2024, then increased by 8.58% to $9.9 billion in 2025, then fell by 12.65% to $8.6 billion in 2026.
Business Quant data shows Revenue for AMGN at $8.6 billion in Q1 2026, $9.9 billion in Q4 2025, and $9.6 billion in Q3 2025.

Peer Comparison